Welcome to Cann Pharma News.
Since its inception, Cann Pharma has established itself at the forefront of phyto-cannabinoid cultivation and development of established therapeutic treatments.
Cann Pharma is dedicated to providing and developing new cannabinoid medicines from our R&D - that address unmet patient needs and can transform lives for patients and their families.
March 30, 2020Earthworks to level the building site for the Greenhouse and Production facility are complete. Water tanks with a volume of one million litres (4x250K tanks) plus solar power water pumps have been installed
July 1, 2019
Cann Pharma received medicinal cannabis Manufacture License from Office of Drug Control (Licence No. ML030/19)
June 5, 2019
Signed a binding term sheet with SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, to develop and supply an oral spray of pharmaceutical-grade cannabinoid derivatives
October 10, 2018
Cann Pharma received development approval from local council in NSW for an $8 million medicinal cannabis farm
September 24, 2018
Cann Pharma signs agreement for Phase 2a Drug Resistant Epilepsy clinical study, with two major hospital sites in Australia
July 11, 2018
Cann Pharma received a medicinal cannabis Import License from Office of Drug Control (Import Licence No. 1820740)
November 9, 2017
Cann Pharma received official notification of a medicinal cannabis Cultivation and Production License from Office of Drug Control
August 16, 2017
Cann Pharma submits application to Office of Drugs Control for license to manufacture medicinal cannabis
December 23, 2016
Cann Pharma signs agreement with leading contract research organisation in Australian for Phase 2a Drug Resistant Epilepsy clinical study
July 1, 2016
Cann Pharma signs agreement with Australian oncology professor for melanoma clinical study, following promising pre-clinical study results in Israel